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1. Introduction
Neutrophils, or polymorphonuclear leukocytes (PMNs), are a key component in the innate
immune system and a powerful player in host defense. Because of this, PMNs have been
studied for over a century, although current understanding of their primary function, traf‐
ficking to sites of infection and catabolyzing microbial pathogens, is unchanged. PMNs are
viewed by some as mere blunt immune instruments, utilized by the host against a broad ar‐
ray of pathogens. However, a careful review of both neutrophil function and dysfunction re‐
veals a cell of discrete coordination in both normal homeostasis and disease. Herein, we
provide a review of neutrophil biology focusing on PMNs role in chronic inflammatory lung
disease. We provide a summary of the current knowledge of these cellular first responders
and detail novel therapeutics related to combating their dysfunction in chronic disease.
2. Evolutionary origin of neutrophils
The evolutionary origins of the human neutrophil lie in phagocytic cells found in simple
organisms. These evolutionary precursors to the human PMNs, originally studied in star‐
fish, were first observed migrating to a site of injury over a century ago. Since the semi‐
nal immunological discovery of cells that attack invading pathogens,  various phagocytic
immune  cells  along  the  evolutionary  continuum  have  been  described.  Phagocytic  cells
with  functions  and signaling  mechanisms  similar  to  mammalian  neutrophils  have  been
described in organisms as  simple as  the slime mold Dictyostelium discoideum.  [1]  Phago‐
cytes  containing  bactericidal  granules  analogous  to  those  in  the  human  neutrophil  are
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found in insects.  Although functionally similar,  these immune cells differ from their hu‐
man  counterparts  significantly  in  lifespan  and  nuclear  morphology,  suggesting  that  a
short-lived,  multi-lobed  phagocyte  is  a  more  recent  evolutionary  development.  [2]  This
trend continues  with  non-mammalian vertebrates.  Both  amphibians  and bony fish  have
granulocytic phagocytes with multi-lobed nuclei that are genetically and morphologically
similar to the human PMN. [3] Although the structure, morphology, function, and genet‐
ic  make-up of  neutrophils  is  highly conserved within mammals,  the percentage of  total
immune cells  represented by neutrophils varies significantly.  Even within primates neu‐
trophil  counts  vary  a  great  deal;  neutrophils  represent  approximately  50% of  chimpan‐
zee’s  circulating  immune cells,  whereas  the  human neutrophil  accounts  for  almost  70%
of white blood cells.  [4],[5] The commonality of PMNs and PMN-like cells make it  clear
that the neutrophil is an ancient player on the immunological stage.
3. Hematopoietic origin, differentiation/maturation of neutrophils
Neutrophil biogenesis occurs in the bone marrow from an undifferentiated hematopoietic
stem cell. Regulation of transcription factors through cytokine and growth factor signaling
dictates neutrophil differentiation, a process called granulopoiesis. Granulopoiesis is the
successive differentiation of a pluripotent hematopoietic stem cell, to a multipotent commit‐
ted myeloid progenitor cell (myeloblast), to a bipotent granulocyte-macrophage progenitor
cell (metamyelocyte) and finally to a unipotent committed granulocyte. The final stage of
PMN maturation, or terminal granulopoiesis, is characterized morphologically by the ap‐
pearance of a multi-lobed granulated nucleus. On a molecular level, granule protein synthe‐
sis and granule packaging mark neutrophil maturation. These granules and their cargo
proteins are among the primary weapons in neutrophils’ antimicrobial arsenal. [6]-[8]Syn‐
thesis of granules and granule proteins progresses concurrently with granulopoiesis. Gran‐
ules are traditionally classified as primary, secondary and tertiary according to the stage of
differentiation during which they are formed. This is important because the granules
formed at different stages of differentiation exhibit drastically different protein cargo and
thus play different roles in the immune and inflammatory response. [9]The array of neutro‐
philic granule cargo might include myeloperoxidase, lactoferrin, haptoglobin and alpha-1-
antitrypsin. [10] Specific granule proteins and their respective roles in neutrophilic lung
disease will be addressed below.
4. Release and homeostasis
Once mature, neutrophils are released from the bone marrow. Locally, release of neutrophils
into circulation is governed by cytokine signaling. Toll like receptors (TLRs) and granulo‐
cyte colony stimulating factor (G-CSF) receptors are crucial in neutrophil production, but
CXCR2 and CXCR4 appear to be the primary receptors involved in neutrophil release into
the circulation. [11],[12] Whereas activation of CXCR4 favors retention of mature PMNs in
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the bone marrow, activation of CXCR2 promotes their release into circulation. Under ho‐
meostatic conditions a normal human adult produces 1 - 2 X 10[11] neutrophils per day. The
rate of neutrophil production and release is dictated largely by G-CSF in a negative feedback
mechanism whereby an increasing number of apoptotic neutrophils decreases the amount of
G-CSF. The apoptotic neutrophils are phagocytosed by tissue macrophages, which decrease
their release of interleukin-23 (IL-23). IL-23 stimulates the release of IL-17 by helper T (TH)
cells. [13] IL-17 is in turn the primary stimulus for the release of G-CSF. Thus, increased con‐
trolled destruction of neutrophils leads to decreased levels of macrophage derived IL-23 re‐
leased by macrophages, IL-17 released by TH17 cells, G-CSF released by osteoblasts, and
thus a decrease in neutrophil synthesis and release. Conversely, IL-17 has been shown to act
through p38 MAPK to augment IL-8 release from pulmonary epithelial cells. This mecha‐
nism, ideally, allows the body to rapidly speed neutrophil production and release during in‐
fection in a regulated fashion to minimize potential damage to the host. [10],[14]Another
method by which the host regulates circulating neutrophil numbers is through the phenom‐
enon of margination and demargination. Margination occurs when resting neutrophils trav‐
el at a significantly slower pace along the endothelium of the blood vessels. The expression
of previously mentioned adhesion molecules creates distinct organ-specific (marginated)
pools of cells. Exercise induced stress, infection, or other sources of systemic stress leads to
an increase in blood flow, a release of epinephrine and demargination of the neutrophil into
the general circulation.[15]
5. Response to infection/smoking
Although the rate of neutrophil production and release may increase during an immunolog‐
ical challenge, as the most populous circulating white blood cells, neutrophils serve as first
line responders to injury and infection. During the course of their 6 to 8 hour life span in
circulation, neutrophils tend to remain near the vascular endothelium. PMNs constitutively
express two glycoprotein ligands, PSGL-1 and L-selectin, allowing neutrophils to detect in‐
flamed or injured endothelium. At sites of inflammation, bacterial peptides such as lipopo‐
lysaccharide (LPS), and f-Met-Leu-Phe (fMLP), along with host pro-inflammatory cytokines
(i.e., tumor necrosis factor-α [TNF-α]) stimulate the vascular endothelium to produce to ad‐
hesion molecules such as lymphocyte function antigen (LFA) and the immunoglobulin-de‐
rived intercellular adhesion molecule (ICAM). [4],[15]
The adhesive force between the endothelial adhesion molecules and neutrophil selectins
produces a Velcro®-like action that slows the neutrophil down, a process known as rolling.
Rolling also prompts the neutrophil to express surface molecules known as β-integrins,
which further slow the neutrophil. It is at this early stage that PMNs have already begun to
become activated and are preparing the intracellular machinery necessary to combat the in‐
vading pathogens. Slow rolling is followed by arrest and firm adhesion via clustering of β2-
integrins. Arrest initiates actin polymerization vital to migration across the endothelial
surface via a G-protein coupled receptor (GPCR) signaling cascade. [16],[17] Transendothe‐
lial migration, or exocytosis, begins as the adhesive force between the neutrophil and endo‐
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thelium increases and the neutrophil “crawls” in search of a suitable route to cross the vessel
wall, either paracellular or transcellular. At this point the neutrophil extends pseudopod-
like surface projections that penetrate the endothelium. Upon penetration the neutrophil in‐
creases expression of surface integrins and releases proteases that function to break through
the vascular basement membrane and into the inflamed tissue. [16]
Once in the interstitium, PMNs must target the specific site of infection amidst large number
of healthy cells. This is accomplished by a two pronged method of sensing inflammatory
chemoattractant gradients. PMNs sense a chemoattractant gradient of IL-8 produced by
damaged host cells and resident monocyte/macrophages through CXCR1 and CXCR2 (both
GPCRs), and also detect fMLP (FPR1 receptor) LPS (TLR4), flagellin (TLR5), through pattern
recognition receptors. [18] Although PMNs have been traditionally thought to promulgate
an active innate immunity with little regulation, more recent evidence suggests that PMNs
carefully coordinate a well-tailored immune response. A classic example of this regulated
coordination is the elegant response of PMNs to IL-8. [19] As PMNs travel along the IL-8
gradient activation and release of microbicidal molecules occurs in a step-wise manner.
With increasing concentrations of IL-8, neutrophils first produce more β-integrins, subse‐
quently begin the oxidative burst, and finally degranulate potent proteases into the intracel‐
lular space. [20] The trafficking of neutrophils to sites of inflammation is with dual purpose:
1) to release their antimicrobial arsenal, and 2) to recruit more neutrophils and other innate
immune cells to the site of inflammation.
The neutrophil’s arsenal includes the following weapons with which the neutrophil attacks
pathogens: release of aforementioned granules with their anti-microbial contents, synthesis
and release of anti-microbial peptides, production of reactive oxygen species (ROS) during
the respiratory/oxidative burst, phagocytosis (mainly utilized to remove debris) and the re‐
lease of neutrophil extracellular traps (NETs), composed of DNA material that entraps in‐
vading pathogens. The second objective is accomplished through the release soluble
mediators such as IL-12 and IFN-gamma that form a complex network of recruitment of oth‐
er neutrophils, dendritic cells, natural killer cells and macrophages. [21] Neutrophils can al‐
so act as antigen presenting cells in communication with CD8+ T cells, thus forming a link
between innate and adaptive immunity. Such a potent response to injury and inflammation
depends on negative feedback mechanisms, the short life span of neutrophils and the clear‐
ance of apoptotic neutrophils by macrophages. If left unchecked, the inflammatory response
mediated by neutrophils can be a major contributor to chronic disease. 4 (Fig. 1)
Neutrophils are capable of responding to a number of inflammatory stimuli other than in‐
fection. Cigarette smoking has been shown to be a primary stimulus for the activation and
migration of neutrophils into the tissues. Neutrophil treatment with cigarette smoke induces
β2-integrin activation and firm adhesion to fibrinogen. Increased levels of neutrophil elas‐
tase, and matrix metalloproteases has been demonstrated with exposure to cigarette smoke.
Furthermore, there is a decrease in superoxide production in the presence of cigarette
smoke, indicating that smoking may lead to an impaired response to bacterial challenge.
It is with this potential for destructive dysregulation that we provide the following review
of selected neutrophil mediated, inflammatory lung diseases. The definition, etiology, epi‐
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demiology, cellular pathophysiology, diagnosis and current treatment of each condition will
be discussed briefly. Following each disease will be a discussion of recent advancements in
the understanding of the disease and advancements in therapeutics directed toward each
condition.
Figure 1. Neutrophils in both normal and chronic inflammatory responses. Neutrophils are recruited into the airway in nor‐
mal acute information through the release of chemokines such as IL-8, IL-17 and LTB4. Once in the airway they release pro‐
teases and reactive oxygen species (ROS) to combat bacteria (shown in red). After the infection in resolved, the neutrophils
undergo apoptosis and prevent destructive release of their proteases and ROS into the interstitium. (A) In chronic inflam‐
mation, neutrophils continue to release harmful proteases with no pathogen presence. Eventually the neutrophils under‐
go necrosis which futher damages the epithelium and creates a feed-forward process of disease. (B)
6. COPD
6.1. Overview and epidemiology
Chronic obstructive pulmonary disease (COPD) is marked by progressive and irreversible
airway limitation, chronic bronchitis, pulmonary hypertension and emphysema. These tis‐
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sue changes are secondary to persistent, chronic pulmonary inflammation in response to
persistent exposure to toxic gases or particles, primarily tobacco smoke. In addition to a
baseline inflammatory state, the disease is associated with frequent exacerbations due to
constant inflammation. [22],[23] Although preventable and treatable, COPD is a significant
cause of morbidity and mortality worldwide. As the leading cause of pulmonary-related
death in the world, COPD was the fifth leading cause of death worldwide in 2001 and is ex‐
pected to move to third by 2020. [24]
6.2. Etiology
An overwhelming proportion of COPD is related directly to cigarette smoking. Other envi‐
ronmental irritants that have been implicated in the development of COPD include coal and
metal mining dust, urban pollution, and indoor cooking with biofuels. [25] Irrespective of
secondary irritants, greater than 90% of individuals diagnosed with COPD are current or
former smokers. However, only a minority of current and former smokers develop sympto‐
matic COPD (15-20%), suggesting COPD is a confluence of environmental factors and genet‐
ic susceptibility. [26] The complex nature of the inflammatory process and its response to
environmental factors in COPD confounds the search for individual susceptibility genes.
[27] To that end, several genome-wide association studies (GWAS) have been performed
with the goal of elucidating the genetic factors related COPD pathogenesis. Unfortunately,
even in this current age of rapid whole genome sequencing, multiple GWAS studies have
only postulated loose corollaries of genes and association with disease. No genes associated
with COPD have displayed a Mendelian mode of inheritance with respect to causation of
COPD. [28]
6.3. Pathophysiology
On a cellular level, the pathophysiology of COPD is essentially a heightened, perpetually ac‐
tive inflammatory process. Inflammation is typically localized in the small airways and pa‐
renchyma of the lungs, where irritant molecules become trapped. The difference between
the normal inflammatory cascade and that seen in COPD is the damage immune cells and
their mediators inflict upon the lung tissues due to persistent activation. Lung function de‐
cline, characteristic of COPD, is linked to three distinct but synergistic mechanisms: destruc‐
tion of alveolar walls (emphysema), narrowing of the small airways, and hypersecretion of
mucus. [29]
The inflammatory cascade leading to COPD is a complex interaction of immune cells and
molecular mediators. The process begins with the inhalation of cigarette smoke or other
chemical irritants, which damages the airway epithelium leading to release of chemoattrac‐
tant molecules. Cigarette smoke was also shown by Braber et al. to induce β2 integrin-de‐
pendant migration of neutrophils across endothelial cells. [30] These ligands bind and
activate chemokine receptors on circulating neutrophils, helper T cells, cytotoxic T cells and
monocytes and recruit them to the lungs. Monocytes migrate across the epithelium and dif‐
ferentiate, joining the resident macrophages. As the congregation of immune cells grows
they release proteases, such as matrix metalloproteinase-9 (MMP-9) and human neutrophil
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elastase (HNE), which degrade connective tissue, particularly elastin, of the alveolar wall,
leading to emphysema. [31]-[33] Airway narrowing results from fibroblast proliferation and
collagen deposition around the bronchioles in response to TGF Β (transforming growth fac‐
tor) released by macrophages and irritated epithelial cells.
6.4. Role of neutrophils in COPD
Neutrophils themselves are a primary factor in the continuation of the pro-inflammatory
state seen in COPD. The hypersecretion of mucus is linked to the accumulation of PMNs.
Neutrophil elastase stimulates mucin gene expression; hence goblet cells and mucus glands
produce excess mucus, leaving the bronchioles further obstructed. [34],[35] HNE is a one of
a family of neutrophil serine proteases that have pluripotent effects in COPD. Not only can
HNE degrade the basement membrane but it also directly affects ciliary beat frequency and
cleaves CD2, CD4, and CD8 on T-cells, affecting their function. Additionally, HNE cleaves
CXCR1 on PMNs, creating an impotent neutrophil that travels to the site of infection but is
incapable of acting once it arrives. [36] Furthermore, other neutrophil proteins such as pro‐
tienase-3, cathepsin G, and myeloperoxidase are all pro-inflammatory molecules released by
the neutrophil upon activation or necrosis. [37]
6.5. Diagnosis of COPD
The current standard for COPD diagnosis is spirometry. Lung spirometry measures the vol‐
ume of exhaled air, thus providing a functional assessment of airway obstruction. Two key
spirometric values are FEV1 (forced expiratory volume), the volume of exhaled air over the
first second of forced expiration, and FVC (forced vital capacity) or the total volume of air
exhaled during forced expiration. These values are interpreted as a ratio (FEV1/FVC) where‐
by a decreasing value indicates increasing airway obstruction. A ratio less than 0.70 after
bronchodilator treatment is diagnostic for COPD. [38],[39] Clinical indications for spiromet‐
ric evaluation include age greater than 40 years, family history of COPD, past exposure to
inhaled irritants, chronic cough and sputum production and dyspnea. [22]
6.6. Traditional COPD therapeutics
Pharmacological therapy of COPD is rooted in combating the symptoms that present sec‐
ondary  to  the  tissue  damage  described  above.  Currently  drug  therapy  is  limited  to  a
small  cadre of  drug classes.  Therapeutic  agents  include bronchodilators,  glucocorticoste‐
roids and phosphodiesterase inhibitors. Bronchodilators are the mainstay of COPD thera‐
py.  Β  2  receptor  agonists  act  on  bronchial  smooth  muscle,  promoting  relaxation  and
airway  dilation.  Both  long  acting  (daily  therapy)  and  short  acting  (acute  exacerbation)
formulations are used. [40] Anticholinergics, or acetylcholine antagonists complement the
airway dilating mechanism of β-agonists by blocking parasympathetic muscarinic recep‐
tors  that  otherwise  cause  bronchial  smooth  muscle  contraction.  [41]  Inhaled  glucocorti‐
costeroids  aid  in  controlling  inflammation,  but  are  typically  only  used  in  conjunction
with  other  drug  classes.  Oral,  or  systemic,  glucocorticoid  therapy  is  reserved  for  acute
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exacerbations because of chronic immunosuppression and undesirable side-effect profiles
from long-term daily use. [42]
7. Cystic fibrosis
7.1. Disease overview
Cystic  fibrosis  (CF)  results  from  a  genetic  defect  in  the  cystic  fibrosis  transmembrane
conductance  regulator  (CFTR),  an  epithelial  cell  ion  transporter.  Although the  resultant
lung pathology is the main source of morbidity and mortality, there is multi-system dys‐
function due to the prevalence of the channel in several cell types. The myriad manifes‐
tations  of  CF  include  lung  disease,  pancreatic  insufficiency  (both  endocrine  and
exocrine), male infertility, liver disease, meconium ileus, and distal intestinal obstruction.
[43],[44]  Among these,  the primary cause of  morbidity and mortality in cystic  fibrosis  is
pulmonary  disease.  Pulmonary  complications  stem  from  impaired  ion  transport  in  the
airways,  which  results  in  thick  mucus,  reduced  ciliary  beat  frequency  and  pathogen
clearance from the respiratory tract. These pathogens constantly bombard and eventually
colonize  the  CF  patient’s  airways,  which  leads  to  a  state  of  persistent  inflammation
marked by recurrent infections and exacerbations. [45]
7.2. Epidemiology/prevalence/survival
CF predominately affects Caucasians, and has an estimated prevalence of roughly 80,000
people worldwide. When it was first described in 1938, CF virtually guaranteed death short‐
ly after diagnosis. However, advances in knowledge of the disease process and clinical man‐
agement of CF have led to improved life expectancy of 25 years in 1985 and currently
approaching 40 years. Individuals diagnosed with CF today are expected to survive beyond
50 years of age. [46]
7.3. Etiology
The cystic fibrosis gene is situated on the long arm of chromosome 7. CF mutations are
transmitted in an autosomal recessive pattern [47] and over 1500 unique mutations of the CF
gene have been identified. [48] Such a large number of different mutations, and the demon‐
strated influence of other genes (i.e. TGFΒ1) suggests the probability of considerable varia‐
bility in genotype, phenotype and disease severity. [49] Indeed, this is the case; symptoms,
onset and severity vary widely across the CF population. CF patients are classified I-VI ac‐
cording to the type of defect the mutation causes in the resultant protein. Class I mutations
are nonsense or stopgain mutations that cause the protein to be truncated. Class II are typi‐
cally missense mutations that affect the tertiary structure of the protein and prevent it from
trafficking to the cell membrane (this is by far the most common type of mutation seen in
CF). The most common of all CFTR mutations is termed ΔF508, a deletion of three nucleoti‐
des resulting in a deletion of phenylalanine at position 508, and is a class II mutation. In
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class III mutations, the CFTR is fully formed and traffics correctly to the cell membrane but
does not function properly upon reaching it. Class IV mutations are similar to that of class
III but they are solely malfunctions in the opening of the channel. Class V mutations result
in less than normal amounts of CFTR, although what is made functions correctly. Finally,
class VI mutations are similar to that of class V but they are unique in that what CFTR pro‐
tein is made is degraded too quickly and there is a functional deficit in the necessary
amount of CFTR present on the apical membrane. [50]Typically genotypes in classes I-III
have worse phenotypic presentations and higher mortality. Like genotype, sex is also a mor‐
tality predictor; males have a higher survival rate than females until the age of 20. [51],[52]
7.4. Pathophysiology
As noted above, CF presents with numerous extra-pulmonary symptoms, but only pulmo‐
nary complications will be addressed herein. Pulmonary manifestations of CF can be under‐
stood as a stepwise melding of the following pathologic processes:
1. Defective CFTR
2. Reduced ASL height
3. Disrupted mucociliary clearance
4. Colonization/chronic infection/exacerbation
5. Neutrophil dominated inflammation
(1) The underlying genetic defect in CF results in either a dysfunctional or absent CFTR
channel. The submucosal glands in the distal airways express CFTR, a protein that spans the
membrane of epithelial cells. It employs a cAMP-mediated, PKA activated mechanism to
conduct chloride ions across the lipid bilayer. Other functions of CFTR that have been de‐
scribed are affected with varying degrees based on the type of mutation (congenital bilateral
absence of the vas deferens). How those secondary functions are altered may explain the
phenotypic severity in CF, but dysregulation and dysfunction in chloride conductance is the
primary pathology of the CFTR in CF.
(2)  Ineffective secretion of  chloride anions (and unregulated absorption of  sodium ions)
leads to a reduced volume of airway surface liquid (ASL) due to the diminished electro‐
lyte content in the airway and very little osmotic pull. In turn, this alters the consistency
of  airway mucus  to  a  thick,  desiccated,  hyper-viscous  layer  that  adheres  to  the  airway
epithelium. [53]
(3) The adherent mucus creates plaques that obstruct the airways and disrupt the mucocili‐
ary clearance mechanism. The detrimental effect of poor mucus clearance is two-fold. First,
lung function, as measured by spirometry, declines due to the physical obstruction of the
airways. Clogged with mucus plugs, the small airways conduct air less efficiently. Second,
the adherent mucus becomes a nidus for infection. [54]
(4) The airways are thus persistently colonized by multiple species of bacteria, namely Pseu‐
damonas aeruginosa, Burkholderia cepacia, Hemophila influezae and Staphylococcus aur‐
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eus. These organisms are difficult to eradicate in the CF patient, even with continuous
prophylactic antibiotic treatment. Colonization is a doorway for infection, and CF is marked
by periods of infection and significant decline in lung function known as exacerbations. The
etiology of CF exacerbations is closely linked to fluctuations in the balance of bacterial flora
in the airway. [55]
(5) Airway obstruction, colonization and episodic exacerbations promote a state of chronic
inflammation in CF. In fact, the clinical status of the CF patient, especially during an exacer‐
bation, is tied more closely to the inflammatory response than the quantity and types of or‐
ganisms responsible for the infection. That inflammatory response is dominated by
neutrophils (PMNs) and is responsible for the bulk of tissue damage in the CF airways.
Bronchoalveolar lavage and sputum specimens from patients during exacerbation reveal
high concentrations of both PMNs and their effectors and signaling molecules, such as neu‐
trophil elastase and IL-8, respectively. [56] IL-8 is a powerful recruiter of PMNs, and excess
levels of this signaling molecule likely explains the PMN dominated inflammation in CF.
Excess PMN recruitment to the lungs results in the discharge of their destructive weapons
(described above) and subsequent killing of pathogens, apoptosis and damage to lung and
airway tissue. More often the extreme inflammatory state leads to an aggregation of dying
PMNs that result in dysregulated cell lysis, or necrosis, instead of a controlled destruction
that mitigates tissue damage. When PMNs undergo necrosis instead of apoptosis they re‐
lease all of the activated enzymes and molecules designed to destroy pathogen into the in‐
terstitial space, further damaging an already taxed pulmonary environment. This damage
results in a collection of mucopurulent debris that further clogs airways and provides a
breeding ground for further infection. [57]
7.5. Diagnosis of cystic fibrosis
The accepted method for diagnosing CF is by quantitative analysis of the chloride ion con‐
tent of the sweat. This is based on the premise that the CFTR protein is expressed in sweat
glands as well, leading to excessive chloride ion concentration in the sweat. DNA immunor‐
eactive trypsinogen screening techniques are available that detect the presence of many of
the common CF mutations. [52],[58] Although not standard, newer diagnostic and screening
techniques include genotyping and measurement of the nasal potential difference. No mat‐
ter what the sweat chloride results, diagnosis of CF remains incomplete without molecular
analysis of CFTR gene. Identification of the mutations, and confirmation of their trans state
is necessary to provide the patient with an accurate prognosis and clear counseling to pa‐
rents as to their future reproductive options. Nasal potential difference assesses ion conduc‐
tance in vivo by observing changes in the voltage potential difference across the nasal
epithelium. [59]
7.6. Current cystic fibrosis therapeutics
Advancements in therapeutics in CF in recent decades are the foundation for the prolonged
survival of individuals noted above. Unfortunately, almost all current therapies the clinician
has at his or her disposal only address the symptoms of CF without correcting the underly‐
Lung Diseases10
ing channelopathy. Current CF therapeutics are best understood in relation to how they ad‐
dress the five pathological processes described above. Efforts to address the underlying
cause of CF, mutations of the CFTR gene, are underway in the form of gene therapy. The
central problem surrounding gene therapy is the search for a suitable delivery mechanism.
Viral vectors have been studied, but immune provocation remains to be an obstacle. [60] Re‐
duced ASL height has been successfully addressed with inhaled hypertonic saline and en‐
zymes, such as recombinant human DNAase (dornase alfa). In conjunction with the
inhalation therapies noted above, techniques such as breathing exercises, positive expiratory
pressure masks, and chest compression (both manual and automated) seek to disrupt the
mucus plaques that line the CF airways. Aggressive antibiotic therapy is employed to com‐
bat both chronic colonization and acute infections. Although inhaled tobramycin and cipro‐
floxacin therapy have been effective, the wide array of bacteria in the CF airway precludes
development of antibiotic therapy protocol. Finally, high dose ibuprofen and macrolide
(typically Azithromycin) treatments stifle the persistent, PMN-dominated inflammation
seen in CF. [46],[61],[62] There have been recent exciting discoveries regarding treatment of
CF and these will be discussed in a later section.
8. Alpha 1 AT
8.1. Overview/epidemiology
α1-Antitrypsin (A1AT) deficiency (A1AD) is a form of COPD that is an extreme form of
the  condition,  with  the  potential  to  develop COPD without  excessive  smoking.  Patients
with  A1AT deficiency  comprise  approximately  5% of  the  global  COPD population  and
have a predicted life span more than 10 years less than those of a life-long smoke with
COPD.  A1AT  is  believed  by  many  to  be  an  underreported  condition  affecting  up  to
1:2000  people.  [63]  Although this  may seem extremely  prevalent,  those  with  the  condi‐
tion  only  begin  to  appear  symptomatic  with  cigarette  smoking.  The  underreporting  of
A1AD may also  be  due  to  clinicians  giving  a  diagnosis  of  idiopathic  COPD,  or  COPD
without a known underlying cause. [64]
8.2. Etiology
A1AD is a genetic disorder inherited in an autosomal recessive manner. Patients with A1AT
have at least two mutations in a trans configuration in the A1AT gene. A1AD patients most
often become symptomatic after cigarette smoking, although it is possible to present with
emphysema in the third decade of life with no prior tobacco use. Patients present with
wheezing, shortness of breath, rales, rhonci, and in some cases, liver failure. [65]
8.3. Pathophysiology
A1AT, an acute phase protein, is member of the serpin family of protease inhibitors. It is
produced in the liver and serves to prevent activation and function of the neutrophil serine
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proteases HNE and proteinase-3. It is normally present at relatively high concentrations
(1.5g/L) in the blood and is believed to play a prominent role in resolving inflammation un‐
der normal homeostasis. A1AD derived COPD is believed to be due to a protease/antipro‐
tease imbalance in which normal levels of HNE and proteinase-3 (P3) are uninhibited at
sites of minor infection or inflammation. [66] The constitutively active HNE and P3 are left
unencumbered to degrade extra-cellular matrix and begin a pro-inflammatory cascade of
molecules that only further exacerbate the inflammation. Cigarette smoking is so destructive
to those with A1AD because cigarette smoke directly inactivates A1AT, wreaking even fur‐
ther havoc on an already taxed system. The pathophysiology of A1AD is similar to that of
COPD and thus the underdiagnosis of this condition.
8.4. Role of neutrophils in A1AD
Very similar to the role they play in traditional COPD, PMNs are both effect and maintain
inflammation seen in COPD. As producers of HNE they are responsible for the initial path‐
ology seen in the condition. [67]Under normal circumstances, A1AT is loosely bound to
HNE, among other serine proteases. However, in the chronic inflammatory condition associ‐
ated with A1AD, HNE is constantly active and degrades the basement matrix. Furthermore,
HNE has been shown to be capable of cleaving the inactive form of MMP-9, pro-MMP-9 to
the active form, creating more protease stress on the system. MMP-9 and HNE are capable
of degrading multiple matrix proteins present in the lung. This destruction of the basement
collagen, elastin, etc. creates a “leaky” vasculature, only making it easier for other immune
cells to move into the lung interstitium. [68] This movement of cells and proteins into the
intracellular space brings with it fluid from the circulation and edema results. As the pro‐
ducers of HNE, neutrophils are integral to the pathogenesis and continuation of A1AD asso‐
ciated COPD.
8.5. Diagnosis of A1AD
Diagnosis of A1AD is only made in those cases of COPD where there is an unexplained
cause of the condition. A1AT serum levels are measured using enzyme linked adsorbent as‐
says (ELISA), or more recently mass spectrometry. Like CF, there is a spectrum of pheno‐
types that are observed in the condition and they are categorized based upon the circulating
levels of A1AT. Patients with the most severe phenotype are those individuals with concen‐
trations less than 15% of normal in their serum. [69]
8.6. Treatment of A1AD
Because of the nature of the disease treatment of A1AD is very similar to that of traditional
COPD, with one exception. Patients with a severe lung phenotype are treated with intrave‐
nous infusion of A1AT isolated from human serum. [70] Additionally, liver transplant has
been utilized to address the absence of circulating A1AT. [71] In addition to these therapies,
the common treatments for COPD mentioned previously are employed to address the spe‐
cific symptoms of A1AD.
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9. Neutrophilic/steroid resistant asthma
9.1. Overview/epidemiology
Asthma was first defined in 1860 by Salter, a British clinician who ascertained that attacks
were related to smooth muscle contraction. Asthma, at its core, is a chronic airway disease
characterized by wheezing, coughing, and breathlessness with variable airway obstruction
on pulmonary function testing. Asthma is a relatively common disease; recent reports by the
Center for Disease Control (CDC) place its prevalence at approximately 12% (children) and
10% (adults) in the US. (www.cdc.gov) There appears to be a predominance of childhood
asthma in non-Hispanic blacks, whereas non-Hispanic Whites, Hispanics, Asians, and Na‐
tive Americans all have similar frequencies of asthma. Additionally, the condition is signifi‐
cantly more common among females than males.
9.2. Etiology
The development of asthma is thought to be associated with three major risk factors: genetic
predisposition, and occupational and environmental factors. Although a precise list of genes
associated with the atopic response in human has yet to be collated, GWAS studies in hu‐
man, and canines have revealed multiple loci related to the IgE response known to be im‐
portant in the etiology of asthma. [72],[73]
9.3. Pathophysiology
Asthma begins in the airways with host contact of an allergen, following this, specific IGE
antibodies are upregulated and initiate mast cell activation. Mast cell activation, in turn be‐
gins the early and late phase response. The early phase response is mediated by histamine,
leukotriene C4, D4, and E4, and prostoglandin D2. After the early phase/hypersensitivity re‐
sponse, that late phase response begins. Eosinophils, basophils, neutrophils, and T cells are
all recruited to the airway and produce inflammatory cytokines that propogate the allergic
response that is a hallmark of asthma.
9.4. Role of neutrophils in neutrophilic and steroid-resistant asthma
Asthma is typically thought of as an eosinophilic disease, yet there have been numerous
studies reporting an increase in neutrophil number and activation in sputum collected from
steroid-resistant asthma patients. There are reports of up to 50% of asthma cases that have
an increase in IL-8 and neutrophil burden, separate from eosinophilic inflammation. [74],
[75] Because of the variability seen in primary immune cell burden in asthma neutrophilic
asthma has recently begun to be viewed as a specific sub-type of the condition. [76] Patients
with neutrophilic asthma have a more severe progression of disease, respond poorly to ther‐
apy, and are burdened with much high health care costs than typical asthma patients. Un‐
fortunately, there is little, if any, established dogma regarding neutrophilic asthma. Studies
have only been able to describe correlative relationships between neutrophil burden and the
phenotypic profile observed in neutrophilic asthma patients. [77] There has been extensive
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work performed investigating the role of MMP-9 in the pathogenesis of asthma. In a report
by Cundall et al the authors state that MMP-9 concentrations in BAL fluid correlate with eo‐
sinophils but not neutrophil or monocyte/macrophage counts. [78] They hypothesize that
PMNs and macrophages release MMP-9 which breaks down the basement membrane, mak‐
ing it easier for the eosinophils to migrate into the airways. In another study, MMP-9 levels
in BAL fluid were correlated significantly with decreases in FEV1 seen in asthma patients.
HNE, another potent neutrophil derived protease, has also been correlated with symptoms
of asthma. [79] Patients with allergic rhinitis has significantly elevated levels of HNE in their
nasal lavage compared to control patients in which no rhinitis was observed. To add to the
myriad of evidence that neutrophils are at the very least, associated with asthma, a study by
Norzila et al demonstrated that myeloperoxidase (MPO), a neutrophil mediator of the oxi‐
dative burst, is elevated in induced sputum collected from certain asthma patients com‐
pared to control patients. [80] Because MPO, HNE, and MMP-9 are all contained in
intracellular granules of the neutrophil it is evidence that neutrophils present in/around the
lung in asthma patients are activated and degranulate.
9.5. Diagnosis of asthma
Diagnosis of asthma is made through evaluation of symptoms and pulmonary function test‐
ing (PFT) via spirometry. An increase in FEV of ≥15% in conjunction with reported wheez‐
ing, chest tightness, and coughing is diagnostic for asthma. A difficulty arises when patients
present with normal spirometry results. To address this, home PFT devices are available to
record lung function data over a period of time to encapsulate more data points. Additional‐
ly, controlled exacerbation of asthma attacks with methacholine in the clinician’s office is a
reliable method of eliciting the necessary response to confirm a diagnosis of asthma. [81]
9.6. Traditional asthma therapeutics
Similar to the other lung diseases discussed in this chapter, treatment of asthma is relegated
to management of symptoms. Monitoring of frequency and severity of attacks is vital to ad‐
ministering correct dosages of medication. Patients are encouraged to keep records of at‐
tacks with information regarding date/time, location, duration, and triggers. The standard
treatment of asthma is glucocorticoid (GC) inhaler with a long-acting β-agonist. [82] The GC
treatment is directed at reducing the constant inflammatory state, whereas the β-agonist is a
bronchodilator intended to ameliorate airway obstruction. So physicians will also prescribe
the use of IgE inhibitors or neutralizing antibodies such as omaluzimab to combat the high
levels of the pro-inflammatory molecule. [83] In neutrophil associated and steroid-resistant
asthma, clinicians have fewer options with which to treat this potentially deadly condition.
A patient’s response to a two week trial of traditional asthma therapy will indicate whether
or not they are a candidate for alternative asthma therapy. Because certain forms of asthma
are refractory to GC therapy, the focus of treatment in such patients shifts to a more aggres‐
sive immunosuppressive approach. Treatment with cyclosporine, tacrolimus, and metho‐
trexate have been associated with some benefit, although the risk of side effects is
significantly higher in these classes of medicines. Finally, IV immunoglobulin therapy is uti‐
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lized in extreme cases, but due to its expense and limited evidence of efficacy, its use is not
widespread. Because of the lack of knowledge about the cellular and molecular etiology of
neutrophilic asthma, current therapies are limited to those already employed in traditional
asthma. As might be expected, these have limited efficacy in patients diagnosed with neu‐
trophilic asthma.
10. Novel therapeutics in neutrophilic lung diseases
With better understanding of neutrophilic lung disease has come more advanced and target‐
ed therapeutics. Towards that end, recent work by the Blalock and Gaggar groups at the
University of Alabama at Birmingham (UAB) has expanded the role of PMNs in multiple
chronic inflammatory lung diseases, including COPD, CF, and BOS. They described a novel
concept of neutrophils proteases producing a neutrophil chemokine from extra-cellular col‐
lagen that acted in a feed-forward mechanism of disease. Seminal papers by Weathington et
al and Gaggar et al detail the step-wise manner in which IL-8 draws PMNs into the intersti‐
tium, upon activation they release MMP-8 and MMP-9 which perform an initial digestion of
collagen from macromolecule size. Subsequently, neutrophils release prolyl endopeptidase
(PE), a serine protease previously only known to be a processor of neuropeptides. PE per‐
forms the final digestion of collagen to the tri-peptide proline-glycine-proline (PGP) from
the PPGP amino acid motif that is repeated over 40 times throughout a single collagen mole‐
cule. [84],[85] PGP binds to the same receptors as IL-8, CXCR1 and CXCR2 acting a neutro‐
phil chemoattractant and activator. [86] The authors showed that not only are the proteases
responsible for PGP production present and elevated in BAL fluid collected from COPD and
CF patients, both stable and in exacerbations, but PGP is also measurably elevated by mass
spectrometry in the BAL fluid of such patients and correlates with PMN burden in disease.
[39],[87],[88] These data indicate that not only is PGP a potential biomarker for chronic in‐
flammatory neutrophilic lung disease, but the system of proteases responsible for PGP’s
production, and the receptors upon which it acts are potential targets for the development of
novel precise therapeutics. Furthermore, work by Hardison et al, and Braber et al have dem‐
onstrated that cigarette smoke and its constituents are capable of acetylating PGP into the
more potent and stable n-terminal acetylated form, AcPGP. [89],[90] AcPGP has proven to
be resistant to degradation by leukotriene A4 hydrolase (LTA4H), a hydrolase/amino-pepti‐
dase also produced a number of cells, including neutrophils. In a 2010 Science paper, Snel‐
grove et al described a novel function for the dual purpose enzyme in resolving acute
neutrophilic inflammation in a mouse model of influenza. [91] It would be extremely useful
to have pharmaco-interventions able to modulate the PGP system of neutrophil inflamma‐
tion, either at the genesis (MMP, PE) or terminus (CXCR, LTA4H).
Although any therapeutics derived from such work may be years away from fruition, there
are other recent advancements that are already making an impact on patient morbidity and
mortality. Kalydeco, a drug produced by Vertex Pharmaceuticals is the first drug developed
that addresses the underlying genetic cause of CF. First released on the market in January of
2012, it is effective in patients that carry the G115D amino acid change. [92] This is a class III
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mutation in which the protein traffics the cell surface but the channel does not function
properly. Kalydeco interacts with the channel and increases the open probability of the
channel. Another Vertex product, currently titled VX-809, is designed to act in patients with
class II mutations (i.e., ΔF508). VX-809 acts in the endoplasmic reticulum, allowing improp‐
erly folded CF protein to pool and undergo corrected folding which results in trafficking to
the cell membrane. [93] Both Vertex products are the result of so-called high throughput
small molecule screening in which hundreds of thousands of small molecules are screened
in a recombinant cell-based assay for an effect on cell function. The discovery of drugs that
address the underlying genetics cause is an exciting advancement in any genetic disease, but
made even more so by the fact that CF is one of the more common, and fatal diseases caused
by a genetic malformation. Whether any of these drugs change the number or activation
state of PMNs in the airway is currently unknown
Patients with COPD, an even larger cohort than those with CF may also soon benefit from
new therapies targeted at resolving the underlying cause rather than merely treating symp‐
toms. There is currently only a single phosphodiesterase 4 (PDE4) inhibitor, Daliresp that is
approved for treatment of COPD in the United States. However, there are clinical trials cur‐
rently underway researching the effects of multiple other PDE4 inhibitors. [94] PD4 is a
cAMP specific phosphodiesterase present, primarily, in inflammatory cells and also in epi‐
thelial cells. Treatment with Daliresp has been shown to reduce the release of pro-inflamma‐
tory cytokines by neutrophils and resident monocyte/macrophages. Unfortunately, there are
several side effects associated with Daliresp and thus the need for better, more targeted
PDE4 inhibitors is apparent. Additionally, there have been recent advancements made in
traditional COPD therapies. The development of ultra-long acting β2 agonists has proved
beneficial in a number of lung diseases, including COPD, A1AT, and asthma. [95] Research
is also underway into the identification of biomarkers for smokers who will develop COPD,
allowing treatment or prevention to possibly begin earlier. Investigators at Weill Cornell
College of Medicine are using a metabolomics approach in a cohort of smokers to establish a
thorough catalogue of abnormal cell changes in airway epithelium after cigarette smoking.
(weill.cornell.edu) Utilizing serum, epithelial lining fluid, and airway epithelial samples, Dr.
Crystal’s group aims to identify the early changes in airway epithelium that indicate if a pa‐
tient will develop COPD later.
McNab et al recently published work detailing their investigation of “compound cg,” a
small molecule that assists in reducing aggregates of abnormal A1AT protein. [96] GC was
effective in an in vitro model of A1AT deficiency and showed significant reduction in At1AT
aggregates by both immunohistochemistry and Western blot analysis. Gene therapy is an‐
other approach, also applicable to CF that is being investigated as a potential source of cur‐
ing the disease in A1AT deficiency. A group at UMass has pioneered a dual gene therapy
approach that addressed both the lung malfunction and liver disease so often associated
with aggregation of mutant protein. In utilizing an adeno-associated virus (AAV) to intro‐
duce corrected protein product in the lung, and microRNAs (miRNA) in the liver to reduce
production of dysfunctional protein, the investigators have presented the possibility of cura‐
tive therapy for patients with A1AT deficiency. [97]
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Many of the therapies previously mentioned are also in use in the treatment of PMN-related
or glucocorticoid resistant asthma. The PDE4 inhibitors, along with ultra-long acting β2 ago‐
nists have begun to be used in combating the airway dysfunction associated with asthma.
[98] There is work being done to abrogate the ability of inflammatory cells such as neutro‐
phils to bind adhesion molecules such as the integrin VLA-4. [99] Furthermore, kinase inhib‐
itors being investigated that target p38 MAPK and PI3K would also effect neutrophil
recruitment and activation in asthma. [100]
11. Conclusion
Chronic neutrophilic airway inflammation is a clinically similar, but foundationally hetero‐
geneous cohort of disease. Although neutrophils are necessary and effective components of
the innate immune system in resolving infection, when dysregulated, they can be potent me‐
diators of devastating inflammation. Current therapeutics in a variety of neutrophilic lung
diseases fail to address the underlying causes of the conditions and yield questionable bene‐
fit to patients. Fortunately, advances in identifications of biomarkers such as PGP and others
afford the opportunity to develop targeted therapeutics aimed at resolving and preventing
the progressive destruction that is a hallmark of chronic neutrophilic lung disease.
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